Iron Bisglycinate Revisited: New Data, Emerging Applications, and Formulator Takeaways

United Kingdom — 3 June 2026

For decades, ferrous sulphate has been the undisputed king of iron supplementation, cheap and readily available. But is its reign truly benevolent? Despite its ubiquity, iron deficiency anaemia remains a widespread public health issue, particularly among women. Are we, as an industry, too comfortable with a cost-effective solution that often compromises patient compliance due to significant gastrointestinal side effects? The rising prominence of iron bisglycinate suggests a collective re-evaluation is overdue, but the commercial realities are complex.

What the Clinical Evidence Actually Shows

The primary advantage cited for iron bisglycinate is its superior tolerability and, consequently, improved adherence compared to traditional ferrous salts. A meta-analysis published in The American Journal of Clinical Nutrition (2019) reviewed several randomised controlled trials, consistently reporting fewer gastrointestinal complaints with bisglycinate. For instance, one study found that only 7% of participants taking 25 mg elemental iron as bisglycinate reported constipation, compared to 28% in the ferrous sulphate group. While the absolute bioavailability difference can be modest, often around 15-20% higher for bisglycinate in some studies, the real-world impact comes from sustained intake. "Improved tolerability is not merely a comfort factor; it directly translates to greater patient compliance and, ultimately, better iron status outcomes," notes Professor Eleanor Vance, a leading haematologist at Imperial College London. However, it is crucial to acknowledge that many studies are funded by manufacturers of chelated iron, necessitating careful scrutiny of methodologies and conclusions. The effect sizes, while statistically significant for tolerability, do not always show dramatically superior iron absorption rates that would justify a substantial price premium solely on that basis.

The Formulation Reality

Formulating with iron bisglycinate presents its own distinct set of challenges. While it is generally more stable than inorganic iron salts, its chelated structure can still be susceptible to degradation under certain pH conditions or in the presence of strong chelators. Achieving optimal dissolution and absorption requires careful consideration of excipients; for example, high levels of calcium or phytates can still modestly inhibit absorption, though to a lesser extent than with ferrous sulphate. The choice of capsule material or tablet coating is also critical to ensure stability and minimise potential interactions. "Formulators must move beyond simply swapping out ferrous sulphate for bisglycinate," advises Dr. Marcus Thorne, a pharmaceutical development consultant. "Consideration of a protective matrix or even enteric coating might be necessary to fully capitalise on its benefits and ensure shelf stability over a 24-month period, especially in humid climates." The hygroscopic nature of some bisglycinate forms also demands careful handling during manufacturing to prevent clumping and ensure dose uniformity.

Market Position and Commercial Viability

The global iron supplements market is projected to reach approximately £3.5 billion by 2028, with chelates like bisglycinate driving a significant portion of the growth, estimated at a CAGR of 7-9%. This growth is spurred by increased consumer awareness of iron deficiency and a willingness to pay for premium, better-tolerated forms. However, this segment operates under significant pricing pressures. While raw material costs for bisglycinate are typically 3-5 times higher than ferrous sulphate, consumers expect a proportionally higher efficacy and user experience. Minimum Order Quantities (MOQs) for high-quality bisglycinate can be substantial, often 500 kg or more, posing a barrier for smaller brands. Manufacturers must achieve competitive pricing whilst maintaining acceptable margins, which can be challenging given the ingredient cost. Building a strong brand narrative around 'gentle iron' and clinical efficacy is paramount to justify the higher retail price point and achieve a healthy 40-50% gross margin.

What This Means for United Kingdom

The UK consumer market shows a strong inclination towards 'gentle' and 'body-friendly' formulations, particularly in the women's health sector. Regulatory bodies like the Food Standards Agency (FSA) permit the use of iron bisglycinate in food supplements, provided it complies with specified purity and labelling standards. The competitive landscape is already populated with established brands offering bisglycinate, meaning new entrants must differentiate through unique formulations, additional co-factors (e.g., Vitamin C, B12, Folic Acid), or compelling marketing. Demand signals suggest a consistent appetite for effective iron solutions that mitigate traditional side effects. The NHS, while primarily relying on ferrous salts, acknowledges the issue of poor adherence, indirectly supporting the market for better-tolerated alternatives in the private sector.

The Bottom Line for Formulators

Formulators should absolutely invest in iron bisglycinate, but with a clear strategic approach. The ingredient offers a compelling answer to the pervasive problem of iron supplement intolerance, especially for the women's health market. However, success hinges on meticulous formulation to maximise absorption and stability, a robust commercial strategy to justify the higher cost, and a clear communication of its tolerability benefits over cheaper alternatives. Without a differentiated product and a strong value proposition, the higher ingredient cost will simply erode margins.